QURE - Uniqure NV - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

402.9M

Cash

555.7M

Avg Qtr Burn

-32.05M

Short % of Float

8.50%

Insider Ownership

4.35%

Institutional Own.

75.16%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HEMGENIX® (etranacogene dezaparvovec-drlb) (AMT-061) Details Hemophilia, Rare diseases, Rare genetic disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AMT-130 Details Huntington's disease, Genetic disorder	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AMT-260 Details Epilepsy, Mesial temporal lobe epilepsy	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AMT-162 Details Amyotrophic lateral sclerosis	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AMT-191 Details Fabry disease, Genetic disorder	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.